METex14 | Clinical Trials Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

17 results for “METex14”

Need more precision?

Filter by phase, recruitment status, country, sponsor, age, and study type.

Refine trial search

Met Non Small Cell Cancer Registry (MOMENT)

700 participants · First posted May 17, 2022

A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer

16 participants · First posted Jun 2, 2026

Retrospective Chart Review and Historical Comparison of Capmatinib vs. Standard of Care for German Adult Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring METex14 Mutations

260 participants · First posted Apr 3, 2023

Active, not recruiting

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

337 participants · First posted Aug 12, 2016

RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU)

182 participants · First posted Dec 13, 2021

QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors

First posted May 10, 2017

Not yet recruiting

Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

30 participants · First posted Sep 5, 2025